<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04298528</url>
  </required_header>
  <id_info>
    <org_study_id>1554107</org_study_id>
    <nct_id>NCT04298528</nct_id>
  </id_info>
  <brief_title>A RCT Comparing Dronabinol to a Placebo for Post-operative Pain in Total Joint Arthroplasty</brief_title>
  <acronym>dronabinol</acronym>
  <official_title>A Prospective, Randomized, Double Blind Trial Comparing Dronabinol to a Placebo in the Management of Post-operative Pain in Total Joint Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Colorado Joint Replacement</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Colorado Joint Replacement</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study was to determine if cannabinoid use decreases narcotic
      consumption in patients undergoing total knee arthroplasty (TKA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects enrolled will be randomized into one of two groups either receiving the study drug
      or a placebo and will be followed for the first 6 weeks with regards to outcomes data.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2020</start_date>
  <completion_date type="Anticipated">February 5, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 5, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morphine Equivalence</measure>
    <time_frame>30 day's post operative</time_frame>
    <description>Morphine Equivalence of pain medication used after a total knee replacement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nausea</measure>
    <time_frame>30 day's post operative</time_frame>
    <description>Patients post operative nausea will be collected as none/mild/moderate/severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Defense and Veterans Pain Scale</measure>
    <time_frame>30 day's post operative</time_frame>
    <description>Patients will keep a pain log after their joint replacement on a scale of 0 - 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Pittsburgh Sleep Quality Index</measure>
    <time_frame>4 weeks and 6 weeks post operative</time_frame>
    <description>To monitor sleeping habits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee Society Score</measure>
    <time_frame>4 weeks post operative</time_frame>
    <description>Patient reported outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KOOS-12 Knee Survey</measure>
    <time_frame>6 weeks post operative</time_frame>
    <description>Patient reported outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Veterans Rand 12-Item Health Survey</measure>
    <time_frame>6 weeks post operative</time_frame>
    <description>Patient reported outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>dronabinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronabinol</intervention_name>
    <description>2.5mg 2 times a day for 30 days after total knee replacement</description>
    <arm_group_label>dronabinol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 times a day for 30 days after total knee replacement</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated informed consent from

          -  Stated willingness to comply with all study procedures and availability to attend all
             required visits for the duration of the study.

          -  Male or Female

          -  Age 21-75

          -  Unilateral total knee arthroplasty at Colorado Joint Replacement

          -  All individuals will be screened for drug use (including cannabis) at their
             preoperative appointment

          -  Ability to take oral medication and be willing to adhere to the dronabinol regimen

          -  For females of reproductive potential: use of highly effective contraception for at
             least 1 month prior to screening and agreement to use such a method during study
             participation.

          -  For males of reproductive potential: use of condoms or other methods to ensure
             effective contraception with partner.

        Exclusion Criteria:

          -  Narcotic use in the past 6 weeks

          -  Regular cannabis use in the past 3 months

          -  Major depression or anxiety disorders

          -  Documented psychiatric illness (e.g. bipolar, schizophrenia)

          -  Seizure disorder

          -  Current or previous history of drug and alcohol abuse

          -  Known allergic reactions to components of dronabinol

          -  Tobacco use in the past 90 days

          -  Treatment with another investigational drug

          -  Patients that cannot receive spinal anesthesia

          -  Patients that cannot receive the standardized multimodal pain medications (i.e.
             Tylenol, gabapentin and meloxicam)

          -  Patients that are not able to go home after leaving the hospital and require a short
             term rehabilitation facility
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rose Johnson</last_name>
    <phone>3032602940</phone>
    <email>roseannjohnson@centura.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Colorado Joint Replacement</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roseann Johnson</last_name>
      <phone>303-260-2940</phone>
      <email>RoseannJohnson@centura.org</email>
    </contact>
    <investigator>
      <last_name>Jason Jennings, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Douglas Dennis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Todd Miner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlie Yang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mauricio Mejia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hannon CP, Calkins TE, Li J, Culvern C, Darrith B, Nam D, Gerlinger TL, Buvanendran A, Della Valle CJ. The James A. Rand Young Investigator's Award: Large Opioid Prescriptions Are Unnecessary After Total Joint Arthroplasty: A Randomized Controlled Trial. J Arthroplasty. 2019 Jul;34(7S):S4-S10. doi: 10.1016/j.arth.2019.01.065. Epub 2019 Feb 4.</citation>
    <PMID>30799266</PMID>
  </reference>
  <reference>
    <citation>Jennings JM, Williams MA, Levy DL, Johnson RM, Eschen CL, Dennis DA. Has Self-reported Marijuana Use Changed in Patients Undergoing Total Joint Arthroplasty After the Legalization of Marijuana? Clin Orthop Relat Res. 2019 Jan;477(1):95-100. doi: 10.1097/CORR.0000000000000339.</citation>
    <PMID>30794232</PMID>
  </reference>
  <reference>
    <citation>Hickernell TR, Lakra A, Berg A, Cooper HJ, Geller JA, Shah RP. Should Cannabinoids Be Added to Multimodal Pain Regimens After Total Hip and Knee Arthroplasty? J Arthroplasty. 2018 Dec;33(12):3637-3641. doi: 10.1016/j.arth.2018.07.027. Epub 2018 Aug 3.</citation>
    <PMID>30170713</PMID>
  </reference>
  <reference>
    <citation>Hayes MJ, Brown MS. Legalization of medical marijuana and incidence of opioid mortality. JAMA Intern Med. 2014 Oct;174(10):1673-4. doi: 10.1001/jamainternmed.2014.2716.</citation>
    <PMID>25156148</PMID>
  </reference>
  <reference>
    <citation>Heng M, McTague MF, Lucas RC, Harris MB, Vrahas MS, Weaver MJ. Patient Perceptions of the Use of Medical Marijuana in the Treatment of Pain After Musculoskeletal Trauma: A Survey of Patients at 2 Trauma Centers in Massachusetts. J Orthop Trauma. 2018 Jan;32(1):e25-e30. doi: 10.1097/BOT.0000000000001002.</citation>
    <PMID>29257781</PMID>
  </reference>
  <reference>
    <citation>Khelemsky Y, Goldberg AT, Hurd YL, Winkel G, Ninh A, Qian L, Oprescu A, Ciccone J, Katz DJ. Perioperative Patient Beliefs Regarding Potential Effectiveness of Marijuana (Cannabinoids) for Treatment of Pain: A Prospective Population Survey. Reg Anesth Pain Med. 2017 Sep/Oct;42(5):652-659. doi: 10.1097/AAP.0000000000000654.</citation>
    <PMID>28796754</PMID>
  </reference>
  <reference>
    <citation>Chan MH, Knoepke CE, Cole ML, McKinnon J, Matlock DD. Colorado Medical Students' Attitudes and Beliefs About Marijuana. J Gen Intern Med. 2017 Apr;32(4):458-463. doi: 10.1007/s11606-016-3957-y. Epub 2017 Jan 17.</citation>
    <PMID>28097606</PMID>
  </reference>
  <reference>
    <citation>Cancienne JM, Patel KJ, Browne JA, Werner BC. Narcotic Use and Total Knee Arthroplasty. J Arthroplasty [Internet]. 2018 Jan [cited 2018 Mar 11];33(1):113-8. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0883540317306952</citation>
  </reference>
  <reference>
    <citation>Menendez ME, Ring D, Bateman BT. Preoperative Opioid Misuse is Associated With Increased Morbidity and Mortality After Elective Orthopaedic Surgery. Clin Orthop Relat Res. 2015 Jul;473(7):2402-12. doi: 10.1007/s11999-015-4173-5. Epub 2015 Feb 19.</citation>
    <PMID>25694266</PMID>
  </reference>
  <reference>
    <citation>Morris BJ, Mir HR. The opioid epidemic: impact on orthopaedic surgery. J Am Acad Orthop Surg. 2015 May;23(5):267-71. doi: 10.5435/JAAOS-D-14-00163.</citation>
    <PMID>25911660</PMID>
  </reference>
  <reference>
    <citation>Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004 Sep;3(9):771-84. Review.</citation>
    <PMID>15340387</PMID>
  </reference>
  <reference>
    <citation>Fitzcharles MA, Häuser W. Cannabinoids in the Management of Musculoskeletal or Rheumatic Diseases. Curr Rheumatol Rep. 2016 Dec;18(12):76. doi: 10.1007/s11926-016-0625-5. Review.</citation>
    <PMID>27832442</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 4, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Colorado Joint Replacement</investigator_affiliation>
    <investigator_full_name>Jason Jennings</investigator_full_name>
    <investigator_title>Orthopedic Surgeon</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

